Our Technology
Proprietary Design Platforms Owned
& Developed by
M-Life™
M-Life’s™ platforms builds upon the revolutionary and controversial idea that structure based representations of molecules are not ‘Prime’. As a consequence of this concept, the Company designed algorithms and processes that reflect the quantum mechanical properties of individual atoms and how they behave in complex biological systems. This was the basis for building entirely new approaches to design new, highly efficacious drugs with low toxicity, faster and more cost effectively than ever before.
P2L™ Platform
The P2L™ or Pattern-to-Lead process begins with the collection of efficacy data from several sources; toxicity modules and models are the same for all therapeutic classes. Efficacy data is curated, removing all inconsistencies. The curated data is then categorized by algorithmic determination of mechanism-of-action. Then the molecules within the curated data set are transcribed into quantum-mechanical (QM) space as a hybrid of structural QM properties. Advanced pattern recognition, proprietary to M-Life™, identifies homologous and variable portions of the QM energy-density pattern. This ‘pattern’ becomes the molecular descriptor for AI determination of molecular-efficacy relationships. This process is used to build a multitude of efficacy models that are evaluated for consistency and concordance by the M-Life™ MiST™ platform. This entire process takes a matter of weeks.
MiST™ Platform
The MiST™ or Molecular in Silico Tomography process/platform integrates all efficacy models along with traditional receptor/ligand docking and evaluates predictive concordance for accuracy. Other MiST™ ‘layers’ including, toxicity, ADME models, drugability and synthesis to create a composited solution. This composited solution set identifies the best scaffolds, most relevant active moeities as well as other features that trade against efficacy (toxicities and other adverse effects).
